MMSI Q1 2026 Earnings Call Summary

Summary of Merit Medical Systems (MMSI) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

Total Revenue: $381.9 million, up 7% year-over-year (5% on a constant currency basis).
Organic Growth: 2.7% constant currency growth, with 3.7% growth excluding divested revenue (DualCap product line).
Non-GAAP Operating Margin: Increased by 47 basis points to 19.7%, the highest first-quarter margin in company history.
Non-GAAP EPS: $0.94, a 9% increase year-over-year, exceeding guidance by $0.07.
Free Cash Flow: $25 million, up 26% year-over-year.
Cash and Cash Equivalents: $488.1 million; total debt obligations remained at $747.5 million.

2. Strategic Updates and Business Highlights

Acquisition: Acquired View Point Medical for $140 million, enhancing the oncology platform with the OneMark Detection Imaging System, expected to significantly expand the addressable market.
New Product Launch: Introduced the Resilience Through-the-Scope Esophageal Stent, targeting a growing market in endoscopy.
Revenue Reporting Changes: Transitioned to reporting revenue in two categories: foundational and therapeutic products, aiming for better alignment and clarity in business performance.
Geographic Performance: U.S. revenue grew by 6.8%, while international sales increased by 3%.

3. Forward Guidance and Outlook

2026 Financial Guidance: Updated to reflect expected contributions from acquisitions, projecting total GAAP net revenue growth of 6.3% to 7.8% year-over-year. Non-GAAP EPS guidance is set at $4.01 to $4.15, reflecting a 5% to 8% increase.
Q2 2026 Expectations: Anticipated revenue between $400 million to $410 million, with a growth rate of 5% to 7% year-over-year.

4. Bad News, Challenges, or Points of Concern

OEM Business Decline: OEM sales declined 14% year-over-year, attributed to inventory destocking and macroeconomic impacts, particularly in the APAC region. However, management expects growth to stabilize in Q2.
Tariff Impact: Anticipated $15 million tariff impact on gross margins, with ongoing uncertainties regarding potential changes in tariff policies.
Geopolitical Risks: Ongoing geopolitical tensions could affect supply chain dynamics and revenue, particularly in the Middle East, although current impacts are deemed manageable.

5. Notable Q&A Insights

WRAPSODY Product Update: Management expressed satisfaction with WRAPSODY's performance, reaffirming guidance of $7 million for the fiscal year.
OEM Growth Outlook: Management indicated optimism for mid-single-digit growth in the OEM segment for Q2, with early signs of order recovery.
Acquisition Strategy: Future acquisitions will focus on strategic fit rather than specific size, with a commitment to maintaining margin accretion.
Supply Chain and Product Recall: Addressed supply chain issues related to a Class I recall in the renal segment, which is expected to have an immaterial financial impact.

Overall, Merit Medical Systems reported a strong start to 2026, with solid revenue growth, strategic acquisitions, and positive operational metrics, while navigating challenges in the OEM segment and external economic pressures.

MMSI — Merit Medical Systems, Inc.